US2014121190A1PendingUtilityA1

Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction

67
Assignee: EMOTIONAL BRAIN BVPriority: Nov 3, 2006Filed: Jan 3, 2014Published: May 1, 2014
Est. expiryNov 3, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Jan Johan Adriaan TuitenJohannes Martinus Maria BloemersRobertus Petrus Johannes De Lange
A61K 31/568A61K 31/519A61K 31/496A61P 15/00A61K 47/40A61K 45/06A61K 9/006A61K 2121/00A61K 31/506
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of 3-alpha-androstanediol, preferably in combination with a type 5 phosphodiesterase (PDE5) inhibitor.

Claims

exact text as granted — not AI-modified
1 . A method to treat sexual dysfunction which method comprises administering to a subject in need of such treatment an effective amount of 3-alpha-androstanediol. 
     
     
         2 . The method of  claim 1  which further includes administering an effective amount of a type 5 phosphodiesterase (PDE 5 ) inhibitor. 
     
     
         3 . The method of  claim 2 , wherein said 3-alpha-androstanediol and said PDE5 inhibitor are administered at essentially the same time. 
     
     
         4 . Use according to  claim 1 , wherein said sexual dysfunction is male sexual dysfunction. 
     
     
         5 . Use according to  claim 1 , wherein said sexual dysfunction is female sexual dysfunction. 
     
     
         6 . A pharmaceutical composition comprising 3-alpha-androstanediol. 
     
     
         7 . The pharmaceutical composition of  claim 6  further comprising a PDE5 inhibitor. 
     
     
         8 . A pharmaceutical composition of  claim 7 , wherein said composition releases said 3-alpha-androstanediol and said PDE5 inhibitor at essentially the same time. 
     
     
         9 . A kit comprising at least one pharmaceutical composition comprising 3-alpha-androstanediol and at least one composition comprising a PDE 5  inhibitor, wherein said kit further comprises instructions in respect to the administration of said compositions. 
     
     
         10 . A kit comprising a pharmaceutical composition according to  claim 7 . 
     
     
         11 . The method of  claim 2 , wherein said sexual dysfunction is male sexual dysfunction. 
     
     
         12 . The method of  claim 3 , wherein said sexual dysfunction is male sexual dysfunction. 
     
     
         13 . The method of  claim 2 , wherein said sexual dysfunction is female sexual dysfunction. 
     
     
         14 . The method of  claim 3 , wherein said sexual dysfunction is female sexual dysfunction.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.